| HOME >> MEDICINE >> TECHNOLOGY |
• You will view opinions from our survey.
That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge for cardiovascular drugs.
Order our report now to gain industry and market information you need
Our report can benefit everybody interested in the industry and market for treating acute coronary syndrome. We give predictions and answers you need. Don't miss out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents
1. Executive Summary
1.1 Acute Coronary Syndrome (ACS) Treatment Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Scope of the Report
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods
2. Cardiovascular Diseases (CVD): Overview
2.1 Financial and Social Costs
2.2 Coronary Artery Disease (CAD)
2.3 Acute Coronary Syndrome (ACS)
2.3.1 Unstable Angina (UA)
2.3.2 Acute Myocardial Infarction (AMI)
2.3.2.1 NSTEMI/Non-Q-wave Myocardial Infarction
2.3.2.2 STEMI/Q-wave Myocardial Infarction
2.4 Most ACS Patients are UA/NSTEMI
2.5 Risk Factors
3. Treatment of Acute Coronary Syndrome
3.1 Therapeutic Categories for ACS
3.2 Antiplatelet Drugs/Platelet Aggregation Inhibitors
3.2.1 ADP Receptor Antagonists/Thienopyridines
3.2.2 Glycoprotein Inhibitors
3.2.3 COX Inhibitors and Aspirin
3.3 Anticoagulants
3.3.1 Heparins
3.3.2 Vitamin K Antagonists and Warfarin
3.4 Fibrinolytics
3.4.1 Streptokinase and Urokinase
3.4.2 Tissue Plasminogen Activators (tPA)
3.4.3 Other Fibrinolytic Agents
3.5 Anti-Ischaemic Drugs
3.5.1 Nitrates
3.5.2 Beta-
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |